


RealRate

PHARMACEUTICAL 2017

Moleculin Biotech Inc. Rank 23 of 292









RealRate

PHARMACEUTICAL 2017



Moleculin Biotech Inc. Rank 23 of 292

The relative strengths and weaknesses of Moleculin Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moleculin Biotech Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 141% points. The greatest weakness of Moleculin Biotech Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 245%, being 242% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	5,222
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,345
Liabilities, Non-Current	0
Other Assets	11,148
Other Compr. Net Income	0
Other Expenses	49
Other Liabilities	88
Other Net Income	0
Other Revenues	0
Property and Equipment	23
Research and Development	1,496
Selling, General and Administrative Expense	2,381

Output Variable	Value in 1000 USD
Assets	16,393
Liabilities	1,433
Expenses	3,926
Revenues	0
Stockholders Equity	14,960
Net Income	-3,926
Comprehensive Net Income	-3,926
Economic Capital Ratio	245%

